Ono Pharma USA: David Trexler, chief commercial officer
Ono Pharma USA (OPUS) has named David Trexler chief commercial officer. His duties include leading the firm’s commercial capabilities in preparation for the planned commercialization of its investigational lead compound, tirabrutinib hydrochloride (ONO-4059, "tirabrutinib"), a Bruton's tyrosine kinase inhibitor and potential treatment for patients with primary central nervous system lymphoma.
Kunihiko Ito, president and CEO of OPUS, said of Trexler, “He has a proven track record of establishing commercial organizations for various pharmaceutical companies as well as successfully executing oncology product launches and delivering impactful programs and services to patients and healthcare providers in the US.”